skin
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) normal health, no infectious diseases, blood diseases, mental diseases, active diseases and serious skin diseases (local ulcers or infections, etc.); (2) have not received any facial cosmetic treatment within 2 months; (3) No history of skin allergy; (4) Normal venous blood platelet count range (100×10^9/L~300×10^9/L); (5) 3 months before blood collection, no drugs affecting platelet function and drugs and health products related to the function of the test; (6) No bad habits (such as smoking, alcohol, drugs, etc.) during pregnancy and lactation.
Exclusion criteria
Exclusion criteria: (1) Grade 3 or 4 gastrointestinal bleeding or varicose bleeding that required blood transfusion or endoscopic or surgical intervention in the 3 months prior to the first dose; (2) People with active hepatitis B (HBSAG and/or HBSAG core antibody positive with =103 copies /mL of HBV-DNA or =200IU/mL) or hepatitis C (HCV antibody positive and/or HCV-RNA positive) requiring treatment; (3) A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or a history of allogeneic bone marrow transplantation; (4) Moderate or severe heart disease; (5) The researcher believes that the subjects are not suitable for participating in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion and rate of improvement of skin moisture, elasticity, stain, oil, scar area and hair growth before and after treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Subjective evaluation of patients' psychology before and after treatment.; | — |
Countries
China
Contacts
Affiliated Sixth People's Hospital, Shanghai Jiaotong University